PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|April 26, 2019
Global Biotech Wins Queen’s Award for Enterprise
Author(s)Pharmaceutical Technology Editors
Biocatalysts, a global biotechnology company, has announced it has been named as one of the winners of the Queen’s Awards for Enterprise in Innovation.
Advertisement
In an April 23, 2019 press release, Biocatalysts, a global biotechnology company, has announced it has been named as one of the winners of the Queen’s Awards for Enterprise in Innovation.
The Queen’s Awards for Enterprise are announced annually and are granted to United Kingdom businesses deemed to have demonstrated ‘outstanding achievement’ in the fields of innovation, international trade, sustainable development, and promoting opportunity through social mobility.
Biocatalysts has been granted an award in recognition of its approach to providing enzyme solutions to its customers. Specifically, the company has been recognized for its MetXtra bespoke software system, which is capable of screening millions of sequences to identify new enzymes in hours.
Rod Sears-Black, Biocatalysts’ managing director, commented in the release, “We are very proud to receive the Queen’s award for Innovation. It recognizes the dedication and commitment of the Biocatalysts team to create this unique offering to the market.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement